Country
Switzerland
Novartis has entered into a licencing and collaboration agreement with Australia-based Mesoblast Ltd to further develop and commercialise remestemcel-L, an allogeneic cell therapy for the treatment of a number of inflammatory disorders.
Full text available to subscribers only. Click here for information on subscribing to MedNous.